Sunil Jaiswal - Akums Drugs VP RD
AKUMS Stock | 609.65 29.00 4.99% |
VP
Sunil Jaiswal is VP RD of Akums Drugs and
Address | Plot no. 131 to 133, Block C, Delhi, India, 110083 |
Phone | 91 11 6904 1000 |
Web | https://www.akums.in |
Similar Executives
Found 2 records | VP Age | ||
Major Varma | KNR Constructions Limited | 69 | |
Sandeep Rajpal | Rico Auto Industries | N/A |
Akums Drugs Leadership Team
Elected by the shareholders, the Akums Drugs' board of directors comprises two types of representatives: Akums Drugs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akums. The board's role is to monitor Akums Drugs' management team and ensure that shareholders' interests are well served. Akums Drugs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akums Drugs' outside directors are responsible for providing unbiased perspectives on the board's policies.
Amrut Medhekar, Chief Business | ||
Arvind Srivastava, President Resource | ||
Sanjeev Jain, MD CoFounder | ||
Sanjay Sinha, President Director | ||
Sunil Jaiswal, VP RD | ||
Shantanu Chobhe, Corporate Head | ||
Sumeet Sood, Chief Officer | ||
Dharamvir Malik, Company Officer | ||
Sandeep Jain, MD Founder | ||
Sanjay Sharma, New Strategy | ||
Jitendra Mishra, Head Technology |
Akums Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akums Drugs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Profit Margin | 0.06 % | ||||
Operating Margin | 0.09 % | ||||
Current Valuation | 134.21 B | ||||
Shares Outstanding | 157.39 M | ||||
Shares Owned By Insiders | 82.61 % | ||||
Shares Owned By Institutions | 5.14 % | ||||
Price To Book | 18.53 X | ||||
Price To Sales | 3.09 X | ||||
Revenue | 42.31 B | ||||
EBITDA | 4.96 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Akums Stock
Akums Drugs financial ratios help investors to determine whether Akums Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Akums with respect to the benefits of owning Akums Drugs security.